NCT07404332 2026-02-115-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory TumorsUniversity of IowaPhase 1 Not yet recruiting35 enrolled
NCT05259709 2025-09-11A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With CemiplimabRegeneron PharmaceuticalsPhase 1 Recruiting50 enrolled
NCT03871348 2025-09-10A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSanofiPhase 1 Terminated77 enrolled
NCT04465487 2025-02-24Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor MalignanciesRegeneron PharmaceuticalsPhase 1 Terminated38 enrolled
NCT04729725 2023-08-14SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIALM.D. Anderson Cancer CenterPhase 1 Terminated3 enrolled